Skip to content

INNOMEDIQ

Active Public limited companyfounded 2008active for 18 yearsLiersesteenweg 173, 2220 Heist-op-den-BergKBO/BCE: BE 0806.491.751 subsidiary of #1 company by staff growth in Heist-op-den-Berg, Wholesale and retail trade sector

Lifetime

17 annual accounts with figures on one time axis
peak of €4.8m in 2023
-not published
lowest -€1,734 in 2009
€2.7m▲ 20.5%
peak of €8.3m in 2025
€8.3m▲ 48.8%
€4.1m▼ 30.6%
peak of 25.8 FTE in 2025
25.8 FTE▲ 4.5%
Board3 names since 2023
2 directors and 1 other
Owners4 names in the annual accounts
consolidates
Documentsfilings and deeds
10-08-202610 days late
2025financial year
Turnover from €13.3m to €15.3m reappointed as statutory auditor 14-10Equity from €5.6m to €8.3mDebts from €5.9m to €4.1mCash from €2.0m to €44,008

Key points

from the 2025 annual accounts

Equity

€8.3m ▲ 48.8%

INNOMEDIQ has made a profit without a break since 2010.

Payment terms

93 days to suppliers
Suppliers
106 to 93
Customers
165 to 144

INNOMEDIQ pays its suppliers 13 days earlier than in 2024. Customers pay 21 days earlier.

Filings

17 annual accounts since 2009
AprilJune31 JulyOctober2010201520202025

Two of the last ten came late. The 2019 accounts came in latest, 33 days after the end of the period.

Board

2 joined · 1 left

2 directors joined and 1 left, the latest change on 17-12-2025. 2 are in office now.

Position in the sector

€2.7m

Higher net result than 95% of companies in retail trade. The sector median is €59,222, over 2,459 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,817 companies had the same profile as INNOMEDIQ has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,817 companies, not a prediction for INNOMEDIQ. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director, , since 17-12-2025
Director, , since 17-12-2025
Auditor,
  • 100%score equity €11.5m (2025) · annual accounts 2023
  • 100%equity of €6.7m (2026) · annual accounts 2021 of
    Since the merger of 23-12-2022, these shares have been held by .
  • consolidatesscore equity €22.2m (2025) · annual accounts 2025
Board & ownership

Recent changes

Merger: INNOMEDIQ takes over CF-SYSTEM (director) and (director) resign · and act as permanent representatives · “De vennootschap heeft tot voorwerp, zowel in België als in het buitenland: -De groothandel, detailhandel…” (deed in Dutch) · General meeting of 30-07-2026 · Gazette deed
Merger proposal: INNOMEDIQ takes over CF-SYSTEM and act as permanent representatives · “Groot- en detailhandel in medische, orthopedische en paramedische artikelen (NACE 47.74); Verhuur en lease van…” (deed in Dutch) · Gazette deed
2 directors appointed, 3 resignations , and resign · , , , and act as permanent representatives · and appointed · General meeting of 17-12-2025 · Gazette deed
reappointed as statutory auditor acts as permanent representative · General meeting of 13-06-2025 · Gazette deed
All 40 events

Comparable companies

same main activity, similar in size and age
Company
INNOMEDIQ Heist-op-den-Berg €15.3m 24.2% 67.1% 25.8
WISSNER -BOSSERHOFF BELGIUM Leuven €9.8m 16.2% 78.2% 32.4
OXYSPHAIR Courcelles €15.9m 16.9% 50.3% 31.1
MEDICONFORT Dour €8.6m 5.6% 50.6% 32.8
FUJIFILM Healthcare Belgium Beveren-Kruibeke-Zwijndrecht €11.3m 3.3% 7.1% 27.1
BeMedico Herzele €17.4m 8.1% 66.2% 14.6
ESPACE -SANTE-MEDITEX Tournai €5.9m 0.8% 42.4% 50.6
-10%0%10%20%€10m€100m€1bnINNOMEDIQEBIT margin

Grey: the largest companies of the sector (retail trade (NACE 47)), without their names. Blue: the sector peers from the table.

These companies have the same main activity as INNOMEDIQ: retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741). They are comparable in size and age: total assets between €4.9m and €12m, founded between 1987 and 2008.

Official details

Source: KBO
Status
Active since 18-09-2008Normal situation
Registered office
14 active companies are registered at this addressSource: KBO register, as of 20 November 2026.
Activity
Retail sale of medical and orthopaedic goods, excluding prescription glasses and lensesNACE 47741and 2 others
Joint committee
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment unit
2.173.330.4312220 Heist-op-den-Berg, registered on 02-10-2008
Financial year end
31 December
Peppol
Reachable via Peppol
Company details

Annual accounts 2025

€12.3m▲ 8.1%
Employeeson 31-12-2025
28▲ 7.7%
Filing
Filed on 10-08-2026
Financials

Companies linked to INNOMEDIQ

Parent and group

Insights on INNOMEDIQ

INNOMEDIQ has existed since 2008. In 2020 the gross margin rose from €819,535 to €3.8m.

Solvency rose in 2025 from 48.8% to 67.1% because of the retained profit and lower debts.

holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about INNOMEDIQ

What is the company number of INNOMEDIQ?
The company number of INNOMEDIQ is 0806.491.751. The VAT number is the same number with BE in front: BE 0806.491.751.
Where is INNOMEDIQ based?
The registered office is at Liersesteenweg 173, 2220 Heist-op-den-Berg.Company details
What does INNOMEDIQ do?
According to the KBO register, the main activity is retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses (NACE 47741).
What is the legal form of INNOMEDIQ?
INNOMEDIQ is a public limited company (NV).
When was INNOMEDIQ founded?
INNOMEDIQ was founded on 18-09-2008.
Is INNOMEDIQ still active?
Yes, INNOMEDIQ is an active enterprise in the KBO register.
How many employees does INNOMEDIQ have?
INNOMEDIQ had an average of 25.8 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does INNOMEDIQ fall under?
In its 2025 annual accounts, INNOMEDIQ states joint committee 200 (Auxiliary committee for white-collar workers).
What is the turnover of INNOMEDIQ?
The turnover of INNOMEDIQ was €15.3m in financial year 2025, according to the filed annual accounts.
Is INNOMEDIQ profitable?
In financial year 2025, INNOMEDIQ made a profit of €2.7m.
Where can I find the annual accounts of INNOMEDIQ?
INNOMEDIQ filed 17 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of INNOMEDIQ due?
INNOMEDIQ must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.